Lipoprotein(a), cardiovascular disease, and contemporary management

Mayo Clinic Proceedings

Volumn 88, Issue 11, 2013, Pages 1294-1311

  Jacobson, Terry A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ANACETRAPIB; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NICOTINIC ACID;

ALGORITHM; APHERESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CORONARY RISK; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG POTENCY; DRUG RESPONSE; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENETIC RISK; HEREDITY; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LPA GENE; PATHOPHYSIOLOGY; POPULATION RESEARCH; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW;

EID: 84888876867     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.09.003     Document Type: Review

References (103)

1. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data [published corrections appear in Arch Intern Med. 2008;168(10):1089 and Arch Intern Med. 2008; 168(10):1096]. Arch Intern Med. 2008;168(6):598-608.
2. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339.
3. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006;296(11):1363- 1370.
4. Berg K, Dahlén G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet. 1997;52(5):254-261.
5. Berg K. A new serum type system in manethe Lp system. Acta Pathol Microbiol Scand. 1963;59(3):369-382.
6. Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein (a) in man. J Clin Invest. 1980;65(6):1483-1490.
7. Scanu AM. Lp(a) lipoproteindcoping with heterogeneity. N Engl J Med. 2003;349(22):2089-2090.
8. Siekmeier R, Scharnagl H, Kostner GM, Grammer T, Stojakovic T, März W. Variation of Lp(a) plasma concentrations in health and disease. Open Clin Chem J. 2010;3:72-79.
9. Frank S, Hrzenjak A, Blaschitz A, Dohr G, Kostner GM. Role of various tissues in apo(a) fragmentation and excretion of fragments by the kidney. Eur J Clin Invest. 2001;31(6):504-512.
10. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353(1):46-57.
11. Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res. 1996;37(12):2569-2585.
12. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein (a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86(6):607-614.
13. Luke MM, Kane JP, Liu DM, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27(9):2030-2036.
14. Edelstein C, Italia JA, Scanu AM. Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase: generation of mini-Lp(a) particles and apo(a) fragments. J Biol Chem. 1997;272(17):11079-11087.
15. Røsby O, Berg K. LPA gene: interaction between the apolipoprotein (a) size ('kringle IV' repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level. J Intern Med. 2000;247(1):139-152.
16. Clarke R, Peden JF, Hopewell JC, et al PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26): 2518-2528.
17. Clarke R, Xu P, Bennett D, et al International Study of Infarct Survival (ISIS) Collaborators. Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study. PLoS Genet. 2006;2(7):e107.
18. Lamon-Fava S, Marcovina SM, Albers JJ, et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res. 2011;52(6): 1181-1187.
19. Hopewell JC, Clarke R, Parish S, et al Heart Protection Study Collaborative Group. Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ Cardiovasc Genet. 2011;4(1):68-73.
20. Deo RC, Wilson JG, Xing C, et al. Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans. PLoS One. 2011;6(1): e14581.
21. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Apolipoprotein (a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012; 60(8):722-729.
22. Virani SS, Brautbar A, Davis BC, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125(2):241-249.
23. Emerging Risk Factors Collaboration; Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412-423.
24. Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176-184.
25. Ariyo AA, Thach C, Tracy R; Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349(22):2108-2115.
26. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein (a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol. 2001; 37(2):434-439.
27. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation. 2000; 102(10):1082-1085.
28. Paultre F, Pearson TA, Wei HF, et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol. 2000;20(12):2619-2624.
29. Tyroler HA, Heiss G, Schonfeld G, Cooper G, Heyden S, Hames CG. Apolipoprotein A-I, A-II and C- II in black and white residents of Evans County. Circulation. 1980;62(2):249-254.
30. Morrison JA, deGroot I, Kelly KA, et al. Black-white differences in plasma lipoproteins in Cincinnati schoolchildren (one-to-one pair matched by total plasma cholesterol, sex, and age). Metabolism. 1979;28(3):241-245.
31. Srinivasan SR, Frerichs RR, Webber LS, Berenson GS. Serum lipoprotein profile in children from a biracial community: the Bogalusa Heart Study. Circulation. 1976;54(2):309-318.
32. Wild SH, Fortmann SP, Marcovina SM. A prospective casecontrol study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants [published correction appears in Arterioscler Throm Vasc Biol. 1997;17(5):1010]. Arterioscler Thromb Vasc Biol. 1997; 17(2):239-245.
33. Shai I, Rimm EB, Hankinson SE, et al. Lipoprotein(a) and coronary heart disease among women: beyond a cholesterol carrier? Eur Heart J. 2005;26(16):1633-1639.
34. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231(4):360-381.
35. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245-1255.
36. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89(1):59-67.
37. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995;274(22): 1771-1774.
38. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323(19):1289-1298.
39. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583-1592.
40. Investigators AIM-HIGH; Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy [published correction appears in N Engl J Med. 2012;367(2):189]. N Engl J Med. 2011;365(24):2255-2267.
41. MRC/Cancer Research UK/BHF Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Clinical Medicine, Medical Sciences Division, Oxford University. HPS2-THRIVE: Preliminary results. January 2013. University of Oxford CTSU website. http://www.ctsu.ox.ac.uk/hps2-thrive/ index.htm. Updated May 2, 2013. Accessed September 15, 2013.
42. Nordestgaard BG, Chapman MJ, Ray K, et al European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31(23):2844-2853.
43. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25): 3143-3421.
44. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem. 2003;49(11):1785-1796.
45. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008;101(10):1428-1436.
46. Chen F, Maccubbin D, Yan L, et al. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol. 2013;167(1):225-231.
47. Ballantyne CM, Davidson MH, McKenney JM, Keller LH, Bajorunas DR, Karas RH. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol. 2008;2(2):79-90.
48. Insull W Jr, Basile JN, Vo AN, Jiang P, Thakkar R, Padley RJ. Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: the SUPREME Study. J Clin Lipidol. 2009;3(2):109-118.
49. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62(12):1959-1970.
50. Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008;8(2):69-81.
51. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low highdensity lipoprotein cholesterol levels. Am J Cardiol. 2003; 91(11):1304-1310.
52. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89(6):672-678.
53. Guyton JR, Blazing MA, Hagar J, et al Niaspan-Gemfibrozil Study Group. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 2000;160(8):1177-1184.
54. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 2000;85(9): 1100-1105.
55. Morgan JM, Capuzzi DM, Guyton Jr. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998;82(12A):29U-34U.
56. Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther. 1996;1(3):195-202.
57. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998;82(12A):74U-81U.
58. Seed M, O'Connor B, Perombelon N, O'Donnell M, Reaveley D, Knight BL. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis. 1993;101(1):61-68.
59. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226(4):271-276.
60. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Cardiol. 1998; 82(12A):35U-38U.
61. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007;192(2):432-437.
62. Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem. 2003; 14(6):298-305.
63. Orth-Gomér K, Mittleman MA, Schenck-Gustafsson K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation. 1997;95(2):329-334.
64. US Preventive Services Task Force. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: Clinical Summary of US Preventive Services Task Force Recommendation. AHRQ Publication No. 12- 05168-EF-4. http://www.uspreventiveservicestaskforce.org/uspstf12/menohrt/menohrtsum.htm. Published October 2012. Accessed September 15, 2013.
65. Hulley S, Grady D, Bush T, et al Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280(7):605-613.
66. Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation. 2002;105(8):917-922.
67. Anderson GL, Limacher M, Assaf AR, et al Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
68. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288(7):872-881.
69. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283(14): 1845-1852.
70. Thompson GR; HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198(2):247-255.
71. Daida H, Lee YJ, Yokoi H, et al Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Am J Cardiol. 1994;73(15): 1037-1040.
72. Daida H, Yamaguchi H. Clinical application and effectiveness of low-density lipoprotein apheresis in the treatment of coronary artery disease. Ther Apher. 1997;1(3):253-254.
73. Nicholls SJ, Tang WH, Scoffone H, et al. Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J Lipid Res. 2010;51(10):3055-3061.
74. Albers JJ, Slee A, O'Brien K, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein (a) to cardiovascular outcomes in the AIM-HIGH trial [published online ahead of print August 7, 2013]. J Am Coll Cardiol. doi: 10.1016/j.jacc.2013.06.051.
75. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013;61(4):440-446.
76. Lavie CJ, DiNicolantonio JJ, Milani RV, O'Keefe JH. Niacin therapy lives for another daydmaybe? [letter]. J Am Coll Cardiol. 2013;61(21):2197-2198.
77. Ito MK, McGowan MP, Moriarty PM; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5(3, suppl):S38-S45.
78. Brown WV, Ballantyne CM, Jones PH, Marcovina S. Management of Lp(a) [published correction appears in J Clin Lipidol. 2010;4(6):548]. J Clin Lipidol. 2010;4(4):240-247.
79. Helfand M, Buckley D, Fleming C, et al. Screening for Intermediate Risk Factors for Coronary Heart Disease: Systematic Evidence Synthesis. Evidence Syntheses, No. 73, 2009. AHQR Publication No. 10-05141-EF-1. http://www.ncbi.nlm.nih.gov/books/NBK35208. Accessed September 15, 2013.
80. US Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(7):474-482.
81. Anderson TJ, Grégoire J, Hegele RA, et al. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2013;29(2): 151-167.
82. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61(11):1146-1156.
83. Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009; 203(2):371-376.
84. Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet. 2011;4(5):565-573.
85. Shiffman D, Chasman DI, Ballantyne CM, Nambi V, Devlin JJ, Boerwinkle E. Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 2009; 102(1):179-180.
86. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of lowdose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293-1304.
87. Marcovina SM, Koschinsky ML. Lipoprotein (a): structure, measurement and clinical significance. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. 2nd ed. Washington, DC: American Association for Clinical Chemistry; 2000:345-385.
88. Kulkarni KR, Garber DW, Marcovina SM, Segrest JP. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res. 1994;35(1):159-168.
89. Heuck CC, Schlierf G. Beta-lipoprotein cholesterol quantitation with polycations. Clin Chem. 1977;23(3):536-540.
90. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41(2):246-255.
91. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000;46(12):1956-1967.
92. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 1997;96(5):1390-1397.
93. Konerman M, Kulkarni K, Toth PP, Jones SR. Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups. J Clin Lipidol. 2012;6(4):368-373.
94. McConnell JP, Baudhuin LM, Berger PB, et al. Lipoprotein(a) cholesterol, but not Lp(a) mass, is an independent predictor of angiographic coronary artery disease and subsequent cardiovascular events in patients referred for coronary angiography. Circulation. 2007;116(16, suppl S):818. Abstract 3608.
95. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105(10):1413- 1419.
96. Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein (a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 2008;118(7):743-753.
97. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157(2):352-360.e2.
98. Gutstein DE, Krishna R, Johns D, et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther. 2012;91(1):109-122.
99. Krauss RM, Wojnooski K, Orr J, et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res. 2012;53(3):540-547.
100. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370(9603):1907-1914.
101. Cannon CP, Shah S, Dansky HM, et al DEFINE Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406-2415.
102. Cannon CP, Dansky HM, Davidson M, et al; DEFINE investigators. Design of the DEFINE trial: Determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009;158(4):513-519.e3.
103. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108-1118.